10/18/2019  4:14:36 PM Chg. -0.98 Volume Bid7:58:47 PM Ask7:58:47 PM Market Capitalization Dividend Y. P/E Ratio
89.46EUR -1.08% 0
Turnover: 0.00
-Bid Size: - -Ask Size: - 19.76 bill.EUR - -

Business description

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas.
 

Management board & Supervisory board

CEO
Dr. Ludwig N. Hantson
Management board
Paul J. Clancy, Anne-Marie Law, Aradhana Sarin, Brian Goff, Ellen Chiniara, Indrani Franchini, John Orloff, Rana Strellis
Supervisory board
David R. Brennan, Christopher J. Coughlin, Deborah Dunsire, Dr. Andreas Rummelt, Dr. Felix J. Baker, Francois Nader, John T. Mollen, Judith Reinsdorf, Ludwig N. Hantson, Paul A. Friedman
 

Company data

Name: Alexion Pharmaceuticals Inc.
Address: 121 Seaport Boulevard,Boston Massachusetts 02210, USA
Phone: +1-475-230-2596
Fax: +1-203-271-8198
E-mail: -
Internet: www.alxn.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 65.65%
IPO date: -

Investor relations

Name: Susan Altschuller
IR phone: +1-475-230-3601
IR Fax: -
IR e-mail: IR@Alexion.com

Company calendar

CW 43 | 10/23/2019 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
65.65%
FMR LLC
 
11.88%
T. Rowe Price Associates, Inc.
 
7.90%
BlackRock, Inc.
 
7.30%
The Vanguard Group, Inc.
 
7.27%